Pharmacokinetics-Based DNA-Encoded Library Screening
Pharmacokinetics-Based DNA-Encoded Library Screening
批准号:
10644211
负责人:
Juan Hu
金额:
$12.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2025-03-31
关键词:
3-DimensionalA549Academic TrainingAddressAlkynesAmino AcidsAreaAzidesBindingBiological AssayBiologyCarboxylic AcidsCareer MobilityCell LineCell Membrane PermeabilityCellsCellular AssayChemicalsClassificationClinicCollaborationsCommunitiesComplexCopperCoupledCyclic PeptidesCysteineDNADataData SetDescriptorDetectionDevelopmentDiagnosticDimensionsDrug KineticsEncapsulatedEngineeringEnvironmentExhibitsFundingFutureGenerationsGoalsGrowthHandHela CellsHumanHydrogen BondingImageIn VitroInstitutionLabelLibrariesLigandsLipidsLiposomesMachine LearningMeasurementMembraneMicrofluidicsModalityModelingMolecularMolecular ConformationPenetrationPeptidesPeriodicityPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPhasePhospholipidsPositioning AttributeProlinePropertyProteinsProteomePublishingRadialReactionResearchResearch PersonnelS phaseScreening ResultSolidSolventsSortingStructureStructure-Activity RelationshipSurfaceTechniquesTechnologyTestingThalidomideTherapeuticTrainingVesicleVisualizationWateracademic preparationassay developmentcareercareer developmentcombinatorialcomputational chemistryconformercycloadditiondesigndrug candidatehigh throughput screeninghigh throughput technologyjob marketmachine learning modelmemberminiaturizemolecular dynamicsmolecular massnext generationnovelnovel diagnosticsnovel therapeuticspre-clinicalpropargylamineprotein protein interactionscreeningskillssmall moleculesmall molecule librariestechnology developmenttool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT
This K99/R00 proposal seeks to expand the space of druggable protein targets through the
development of novel analytical technology that will guide the design of next-generation, non-
Lipinski molecular therapeutics and diagnostics. Cyclic peptides, which are not drug-like (i.e., Lipinski-
like), hold great promise for addressing undruggable targets, especially protein-protein interactions (PPIs).
However, the larger molecular mass and more complex secondary structures result in unpredictable and almost
always low cell permeation, significantly blunting their utility as drug candidates and even as preclinical tool
compounds in cells. Rarely, a cyclic peptide will exhibit anomalously high permeation. However, insufficient data
exist to uncover the rules dictating permeation because high-throughput measurements of cell permeation
simply do not exist. In this proposal, a high-throughput in vitro permeation assay compatible with DNA-encoded
combinatorial library (DEL) screening will be developed and miniaturized to the microfluidic droplet scale. The
permeation assay will be applied to screen DELs to identify the species that efficiently permeate membrane
bilayers. The permeable macrocycle hits will be further validated in a cell-based permeation assay that will also
be developed in the project. The large screening data sets will reveal relationships between permeability and
structure, especially for molecules of beyond the Rule of 5 (bRo5), which will be further analyzed using machine
learning. With these and other empirically derived models of macrocyclic peptide pharmacokinetic properties in
hand, we may finally be able to move such non-Lipinski molecules from the lab to the clinic at scale. This proposal
will significantly enhance the PI’s career development and advance her toward her career goal of becoming an
independent investigator at a research-focused institution. The proposed project provides training in cutting-
edge research skills, including cell-based assay development and high-content imaging, DEL design, synthesis
and screening technology development, and machine learning techniques. UC Irvine provides an ideal
environment for academic training, with world-renowned experts in medicinal and computational chemistry,
chemical biology and microfluidics engineering. In addition, UCI provides an intellectual environment that
encourages collaboration and cooperation, enabling the candidate’s growth as a member of the scientific
community. Indeed, the PI will engage in activities designed to achieve independence, including training in lab
management and grantsmanship, networking, and preparation for the academic job market. In summary, the
proposed plan will enable the PI’s scientific and career-wise growth and independence, further positioning her
to attain future R01 funding.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
-
批准号:22007020
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:周志
-
依托单位:
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:周志
-
依托单位:
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
-
批准号:81473017
-
项目类别:面上项目
-
资助金额:66.0万元
-
批准年份:2014
-
负责人:孙涓
-
依托单位:
用于识别癌细胞A549的磁共振和荧光双功能探针的研究
-
批准号:21305156
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2013
-
负责人:陈世桢
-
依托单位:
DNA甲基化参与非小细胞肺癌细胞(A549/DDP)顺铂耐药的研究
-
批准号:81101650
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:张有为
-
依托单位:
白藜芦醇诱导人肺癌A549细胞PML蛋白自噬性降解的机制研究
-
批准号:81172089
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:李冠武
-
依托单位:
Id3在肺腺癌中的表达分析及其对A549肺腺癌细胞增殖影响的机制研究
-
批准号:81171652
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:李晓军
-
依托单位:
hTERT启动子调控下CD137L在肺癌A549细胞中的表达及其抑制肿瘤免疫的实验研究
-
批准号:81172140
-
项目类别:面上项目
-
资助金额:64.0万元
-
批准年份:2011
-
负责人:束永前
-
依托单位:
姜黄素调控肺腺癌A549细胞株SP细胞Wnt信号通路的研究
-
批准号:81001578
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2010
-
负责人:李小江
-
依托单位:
PTEN抑制A549肺癌细胞趋电性及调控直流电场对肺癌转移诱导的研究
-
批准号:81000938
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:闫小龙
-
依托单位: